To study the effect of daily irradiation on the growth of blood vessels in cancer of the gullet

Phase 1

• Conditions: Angiogenesis in esophageal cancer; MedDRA version: 20.0Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 100000004864; MedDRA version: 20.0Level: LLTClassification code 10030151Term: Oesophageal cancerSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2013-002563-25-NL
• Lead Sponsor: VU University Medical Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09-19
• Last Update Posted: 12 March 2018

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

(1) Patients that will receive standard chemoradiation treatment before surgery for oesophageal adenocarcinoma
(2) Ability to give informed consent
(3) Age 18 years or older
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 25
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 25

Exclusion Criteria

(1) Evidence of bleeding diathesis, coagulopathy, prolonged INR or PTT
(2) Pregnancy
(3) Inflammation of the gastro-intestinal tract
(4) Brain metastasis
(5) Diastolic/ systolic Hypertension (>90/>140 mmHg), not responding to treatment
(6) Arterial thromboembolism in medical history
(7) Surgery within the month prior to start of bevacizumab treatment

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified